BioSyent Inc.
RX.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 39.91% | 44.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.91% | 44.16% | |||
| Cost of Revenue | 54.54% | 68.47% | |||
| Gross Profit | 34.52% | 36.89% | |||
| SG&A Expenses | 38.68% | 19.64% | |||
| Depreciation & Amortization | 110.10% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 47.69% | 40.81% | |||
| Operating Income | 16.29% | 55.36% | |||
| Income Before Tax | 18.33% | 32.88% | |||
| Income Tax Expenses | 16.68% | 93.78% | |||
| Earnings from Continuing Operations | 18.99% | 18.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.99% | 18.02% | |||
| EBIT | 16.29% | 55.36% | |||
| EBITDA | 27.41% | 61.20% | |||
| EPS Basic | 18.43% | 17.18% | |||
| Normalized Basic EPS | 13.18% | 42.96% | |||
| EPS Diluted | 18.72% | 17.08% | |||
| Normalized Diluted EPS | 13.49% | 42.90% | |||
| Average Basic Shares Outstanding | 0.50% | 0.66% | |||
| Average Diluted Shares Outstanding | 0.27% | 0.77% | |||
| Dividend Per Share | -2.27% | 10.31% | |||
| Payout Ratio | -0.17% | -0.07% | |||